ライフサイエンスコーパス: immunocompetent

1 s of age categorized as immunocompromised or immunocompetent.

2 immunosuppressed, whereas SRS2 is relatively immunocompetent.

3 immunocompromised populations compared with immunocompetent.

4 18 years categorized as immunocompromised or immunocompetent.

5 ividuals and recurrent ocular lesions in the immunocompetent.

6 One hundred and seventy-three patients (56 immunocompetent, 117 immunocompromised) were included.

7 Taken together, we developed an advanced immunocompetent 3D skin model to investigate epidermal-T

8 replication, and antibody neutralization in immunocompetent adult mice inoculated in the rear footpa

9 t of antifungal prevention in critically ill immunocompetent adult patients on mortality and subseque

10 An immunocompetent adult received corticosteroids for chest

11 do not, without adaptation, cause disease in immunocompetent adult rodents.

12 An immunocompetent adult with asthma developed severe human

13 An immunocompetent adult with asthma developed severe human

14 In immunocompetent adults >/=65 years of age, PCV13 elicits

15 five elements: (1) Incidence estimated from immunocompetent adults >=50 years unvaccinated with zost

16 tudied-exceeding expected HZ incidence among immunocompetent adults >=60 years.

17 r for immunocompromised adults compared with immunocompetent adults (IRR, 2.9 [95% confidence interva

18 with an efficacy >90% against HZ in healthy immunocompetent adults aged >=50 years after vaccination

19 tion comprised: (1) incidence estimated from immunocompetent adults aged >=50 years unvaccinated with

20 d, exceeding the expected HZ incidence among immunocompetent adults aged >=60 years.

21 mplementing different vaccine strategies for immunocompetent adults comparing Spanish regions using P

22 s, together with gene expression profiles in immunocompetent adults experiencing a severe primary HCM

23 Emory University that enrolled non-pregnant, immunocompetent adults from Atlanta, GA, USA, who were a

24 Vaccination with PCV13 in immunocompetent adults seems to control IPD cases by PCV

25 tion for PCV13 use), 57% (95%CI:-62, -52) in immunocompetent adults with chronic medical conditions (

26 or PCV13 use), 57% (95% CI, -62% to -52%) in immunocompetent adults with chronic medical conditions (

27 ed incidence rate ratios (IRRs) comparing to immunocompetent adults.

28 ded incidence rate ratios (IRR) comparing to immunocompetent adults.

29 Thus, this immunocompetent age-dependent ferret model should be use

30 nces declined after PCV introduction in both immunocompetent and iatrogenically-immunosuppressed indi

31 dy, we examined mucosal infection in several immunocompetent and immunocompromised mouse strains.

32 eatments, and outcomes were compared between immunocompetent and immunocompromised.

33 al protection against ZIKV infection in both immunocompetent and immunodeficient mice, highlighting t

34 d with the PET isotope (89)Zr and studied in immunocompetent and immunodeficient mouse models.

35 acy, mechanisms and safety of TSO therapy in immunocompetent and immunosuppressed animals.

36 Moreover, MAYV/IRES vaccination of immunocompetent and interferon receptor-defective mice r

37 A robust immunocompetent animal model is still lacking, hampering

38 ted tumors in both the immunocompromised and immunocompetent animal models demonstrate decreased phos

39 for the development of macaques and pigs as immunocompetent animal models to study HBV infection in

40 or agents for multiple targets in syngeneic, immunocompetent animal models.

41 irus (HCV), for which there are no efficient immunocompetent animal models.

42 development has been hampered by the lack of immunocompetent animal models.

43 th an otherwise identical IgG in a syngeneic immunocompetent animal, and we identify TNFalpha/MCP-1 s

44 model of myocardial ischemia/reperfusion in immunocompetent animals may have significant translation

45 NC research, including immunocompromised and immunocompetent animals.

46 icient animals in comparison to ticks fed on immunocompetent animals.

47 lytic activity in comparison to ticks fed on immunocompetent animals.

48 clearance of the transfected cells occurs in immunocompetent animals.

49 antibodies were detected in the sera of all immunocompetent animals.

50 icient animals in comparison to ticks fed on immunocompetent animals.

51 The abundance of immunocompetent antigen presenting cells (APCs) within t

52 Subcutaneous transplantation into immunocompetent as well as immunodeficient mice resulted

53 In vivo experiments were carried out on immunocompetent BALB/c mice bearing the same syngeneic t

54 Ex vivo tracer biodistribution in immunocompetent BALB/cOlaHsd (BALB/c) mice was performed

55 e peritumoral microenvironment evolves in an immunocompetent brain is unclear.

56 yet lost upon passage of such cells through immunocompetent (but not immunodeficient) mice.

57 nnii strain (LAC-4) that is hypervirulent to immunocompetent C57BL/6 and BALB/c mice and established

58 We pre-exposed immunocompetent C57BL/6 and immunocompromised A129 or IF

59 mediated more potent antiglioma activity in immunocompetent C57BL/6 but not immunodeficient athymic

60 n vivo model of Cryptosporidium infection in immunocompetent C57BL/6 mice by isolating parasites from

61 and IL-17 production by lung lymphocytes in immunocompetent C57BL/6 mice over time following infecti

62 days) without systemic immunosuppression in immunocompetent C57BL/6 mice.

63 ction in vitro in the presence of serum from immunocompetent C57BL/6 or immunocompromised mice lackin

64 Five immunocompetent C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mi

65 Long-term toxicity studies in healthy, immunocompetent CD-1 mice revealed kidney as the dose-li

66 Intracranial inoculation of 1-d-old immunocompetent CD-1 mice with 1 x 10(4) infectious focu

67 vides a biomarker for microglia, the primary immunocompetent cells of the brain.

68 A status) population of T1D patients, to the immunocompetent cells of the skin.

69 Skin is replete with immunocompetent cells that modulate signaling pathways t

70 isease characterized by many dysfunctions of immunocompetent cells.

71 Eighteen percent (36 of 203) of immunocompetent children had been previously vaccinated.

72 Immunocompetent children were recruited as controls.

73 bacterial responses, is common in previously immunocompetent children with influenza-related critical

74 Two hundred three (62%) were immunocompetent children; including 5 of 8 children who

75 Neither the proportion of adult cases with immunocompetent comorbidities (relative risk ratio [RRR]

76 colon organoids we describe a broadly usable immunocompetent CRC model that recapitulates the entire

77 fungal prevention of systemic candidiasis in immunocompetent critically ill adults did not reduce mor

78 is also tested for islet encapsulation in an immunocompetent diabetes rodent model.

79 ted nanoparticles restore normal glycemia in immunocompetent diabetic mice for at least 6 weeks, can

80 -CMV infection was frequently observed among immunocompetent elderly patients with comorbidities or s

81 to more severe concomitant illnesses in the immunocompetent group.

82 disease that were more severe than those in immunocompetent hamsters, notably weight loss, viral loa

83 son to person and cause highly lethal HPS in immunocompetent hamsters.

84 Reinfection was confirmed in a young, immunocompetent health care worker as viral genomes deri

85 ted]) or low risk (aged 3 years or older and immunocompetent [HIV-negative]).

86 te immune sensors, development of additional immunocompetent HNSCC mouse models, as well as engineeri

87 One of them was immunocompetent host and had keratitis with radial kerat

88 mmune activation in DENV target organs of an immunocompetent host and supports the further developmen

89 plete tumor regression, and 100% survival of immunocompetent host mice.

90 cilitate the survival of cancer cells in the immunocompetent host, a concept defined as compensatory

91 cystis infection induces lung disease in the immunocompetent host.

92 ivo system for the study of METDelta14 in an immunocompetent host.

93 ropism-dependent provirus elimination in the immunocompetent host.

94 ther exploration of this adapted antibody in immunocompetent hosts and introduction of this adaptatio

95 morbidity and sometimes fatal infections in immunocompetent hosts and is thus an important pathogen

96 The human tumors emerged in immunocompetent hosts and were extensively infiltrated b

97 norovirus cell tropism in orally inoculated, immunocompetent hosts at the peak of acute infection and

98 While immunocompetent hosts do not typically show symptoms of

99 neously growing syngeneic prostate tumors in immunocompetent hosts improved animal survival after sur

100 ion from engineered mouse cells grafted onto immunocompetent hosts increased insulin secretion and re

101 latency; however, long-term EBV infection in immunocompetent hosts is limited to B cells with a more

102 eria for deferring HSV PCR testing of CSF in immunocompetent hosts with normal CSF white blood cell a

103 l papillomaviruses suppresses skin cancer in immunocompetent hosts, and the loss of this immunity-rat

104 els that recapitulate disease progression in immunocompetent hosts.

105 be exacerbated by inflammatory responses in immunocompetent hosts.

106 fected neurons in both immunoincompetent and immunocompetent hosts.

107 ty of the virus to replicate specifically in immunocompetent hosts.

108 t concordant evidence in well-characterized, immunocompetent human cohorts, demonstrating association

109 Immunocompetent humans and animals, however, can tolerat

110 hypoxia compared to the original tumours in immunocompetent humans, and hypoxia was reduced by adopt

111 IS) hosts, but an M2 predominant response in immunocompetent (IC) hosts following Pneumocystis carini

112 Hosts are considered immunocompetent if they are >/=2 years old and have not

113 While HSV-1 can remain static in an immunocompetent individual for decades, the virus from t

114 e overall mortality of viral encephalitis in immunocompetent individuals is low, suggesting efficient

115 h tropism for B lymphocytes and infection in immunocompetent individuals is typically asymptomatic an

116 B19V DNA-positive serum samples from 222 immunocompetent individuals were analyzed for (1) viral

117 ssess presumptive evidence of immunity among immunocompetent individuals with uncertain immune or vac

118 nvasive intestinal mucormycosis occurring in immunocompetent individuals without the traditional risk

119 ng of the immune response to EBV in healthy, immunocompetent individuals, in transplant recipients, a

120 ive in controlling HSV-1 or -2 infections in immunocompetent individuals, their use in immunocompromi

121 prevalent and maintains chronic infection in immunocompetent individuals, with the potential to repli

122 risk factor for progression to TB disease in immunocompetent individuals.

123 es unnoticed, causing mild or no symptoms in immunocompetent individuals.

124 sk factor for progression to tuberculosis in immunocompetent individuals.

125 ms involved during primary HCMV infection in immunocompetent individuals.IMPORTANCE HCMV-specific imm

126 ption necessitating surgery in a 7-month-old immunocompetent infant with concurrent primary wild-type

127 Although most immunocompetent infected individuals remain asymptomatic

128 r for immunocompromised adults compared with immunocompetent (IRR=2.9, 95% CI 2.9-3.0) and ranged acr

129 V infection is generally asymptomatic in the immunocompetent, it can have devastating consequences in

130 Moreover, RHV has been adapted to infect immunocompetent laboratory mice.

131 of immune control, we sought an outbred and immunocompetent laboratory mouse strain in which persist

132 n E)(-/)(-) mice) in addition to established immunocompetent LDLR(-/)(-) and ApoE(-/)(-) mice.

133 single dose protection against ZIKV using an immunocompetent lethal mouse challenge model.

134 In this study, we combined immunocompetent lineage tracing mouse models of GBM with

135 rain is able to rapidly germinate within the immunocompetent lung environment, inducing greater lung

136 V1 is sexually transmitted in unmanipulated, immunocompetent male and female mice.

137 SKH-1 hairless and immunocompetent mice (n = 180) were fed AIN-93G or AIN-9

138 describes a novel model of MAYV infection in immunocompetent mice and highlights the potential role o

139 an asymptomatically colonize the GI tract in immunocompetent mice and modifies the host GI microbiota

140 ignant gliomas were established in syngeneic immunocompetent mice and then treated with dendritic cel

141 ificantly faster clearance than unvaccinated immunocompetent mice and unvaccinated CD4-depleted mice

142 of a murine norovirus inoculated orally into immunocompetent mice are macrophages, dendritic cells, B

143 Since immunocompetent mice are resistant to infection with S.

144 diation-induced neurocognitive decrements in immunocompetent mice can be resolved by systemic deliver

145 Specifically, vaccinated immunocompetent mice had significantly faster clearance

146 ntar inoculation of a WT strain of MAYV into immunocompetent mice induced persistent hypernociception

147 nd adaptive responses previously observed in immunocompetent mice inoculated with trophic forms compa

148 urprisingly, after peripheral inoculation of immunocompetent mice on the day of birth, the first cell

149 that the host response to DENV infection in immunocompetent mice recapitulates transcriptional chang

150 plantation of S2 and S4 MB49 sub-clones into immunocompetent mice resulted in lung metastases in 50%

151 be adoptively transferred and vaccinated in immunocompetent mice resulting in the expansion of durab

152 Tumors in MFP-treated immunocompetent mice showed increased infiltration of F4

153 Three strains of immunocompetent mice supported mucosal infections.

154 f murine astrovirus that cause infections in immunocompetent mice that mirror aspects of asymptomatic

155 s in the female cervicovaginal epithelium of immunocompetent mice that progress to cancer.

156 oculation into the uterine wall of pregnant, immunocompetent mice to evaluate transplacental transmis

157 Bone marrow cells from immunocompetent mice were isolated, purified for HSC-con

158 he stiff ones (> 700 Pa) can form a tumor in immunocompetent mice with 100 cells per inoculation.

159 s: PET images and ex vivo biodistribution in immunocompetent mice with [(89)Zr]Zr-DFO-N-suc-muS110, t

160 irus-mediated Rex1 ablation in liver of male immunocompetent mice with HCC, induced by hydrodynamic t

161 ce with melanomas derived from patients, and immunocompetent mice with mouse melanomas, had more mela

162 skin cancer, we colonized several strains of immunocompetent mice with mouse papillomavirus type 1 (M

163 A single intramuscular immunization of immunocompetent mice with the MVA-ZIKV-NS1 vaccine candi

164 administration of nonradiolabeled muS110 to immunocompetent mice, (89)Zr-muS110 uptake in the spleen

165 n metastasis models in immunocompromised and immunocompetent mice, and tested the fate and efficacy o

166 ells engineered to secrete erythropoietin in immunocompetent mice, as well as transgenic human cells

167 (P <= 0.001 each), during acute T. gondii in immunocompetent mice, compared to controls.

168 n of ICL-labeled cells in immunodeficient or immunocompetent mice, few cells arrived in the BM intact

169 s increased during Pneumocystis infection in immunocompetent mice, IL-17A is not required for control

170 tumors grow when implanted in the tongue of immunocompetent mice.

171 ffect mimicked by CD8(+) T-cell depletion in immunocompetent mice.

172 e could elicit inflammatory disease in fully immunocompetent mice.

173 contribute to treatment induced toxicity in immunocompetent mice.

174 ), can be exploited to eradicate sarcomas in immunocompetent mice.

175 tant and assessed its virulence potential in immunocompetent mice.

176 ebral bodies, or inoculated in the tibiae of immunocompetent mice.

177 n inhibited growth of HCC cells in syngeneic immunocompetent mice.

178 were injected into the left flank of C57Bl6 immunocompetent mice.

179 r blocking studies were performed on CD1-IGS immunocompetent mice.

180 m a tumor with only 100 cells in NOD-SCID or immunocompetent mice.

181 uptake was lower in immunodeficient than in immunocompetent mice.

182 nsplantation in the intraperitoneal space of immunocompetent mice.

183 ubstantive infection of the brains of normal immunocompetent mice.IMPORTANCE The Ebola virus glycopro

184 of the lower genital tract in heterozygous (immunocompetent) mice of the NU/J strain progressed to h

185 In an immunocompetent model of TNBC in which Eo771/MUC1-C cell

186 cted by presence of an immune response in an immunocompetent model using a mammary carcinoma.

187 underscoring the urgency to develop reliable immunocompetent models for mechanistic assessment.

188 ize host immune activation using preclinical immunocompetent models in previously untested common adu

189 increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs.

190 When coadministered in immunocompetent models, the combination of niraparib and

191 s and preclinical investigations in accurate immunocompetent models.

192 allogeneic glial-restricted progenitors from immunocompetent mouse brains.

193 ium, while Sateriale et al. (2019) report an immunocompetent mouse model facilitating vaccination-ind

194 We tested this hypothesis in an immunocompetent mouse model for ovarian cancer and found

195 me course characterization of our syngeneic, immunocompetent mouse model of endometriosis revealed th

196 epileptogenesis in a genetically tractable, immunocompetent mouse model of glioma, allowing the comp

197 p53-deficient tumors in a highly aggressive, immunocompetent mouse model of lung adenocarcinoma impro

198 h factors will be critical for developing an immunocompetent mouse model supporting HCV replication.

199 as further impetus for the development of an immunocompetent mouse model that can serve as a disease

200 as further impetus for the development of an immunocompetent mouse model that can serve as a disease

201 lele induced lung adenocarcinoma in a novel, immunocompetent mouse model.

202 y of Zika virus-induced motor deficits in an immunocompetent mouse model.

203 inical candidate that can be tested in fully immunocompetent mouse models and its binding epitope can

204 I:C and CpG with trastuzumab-like therapy in immunocompetent mouse models of ErbB2(+) breast cancer.

205 In immunocompetent mouse models of HER2/ErbB2-driven breast

206 -specific CAR-T cells in immunodeficient and immunocompetent mouse models.

207 ctivation is often explored using rat Abs in immunocompetent mouse models.

208 vaccines in a human STAT2-knockin transgenic immunocompetent mouse showed complete protection against

209 rly Mycobacterium abscessus) infection in an immunocompetent mouse strain, especially in the context

210 ntal exposure to the Zika virus in different immunocompetent mouse strains provides a foundation for

211 nfections in different immunocompromised and immunocompetent mouse strains.

212 In this study, we describe an immunocompetent mouse tumor model that exhibits bispecif

213 and enhanced antitumor efficacy in multiple immunocompetent mouse tumor models.

214 best characterized MPS-I murine model is an immunocompetent mouse, we here developed a transplantati

215 ient survival, and here we demonstrate in an immunocompetent murine model that colon tumors expressin

216 se to anti-PD-1 therapy using two orthotopic immunocompetent murine models of non-small cell lung can

217 and is suitable for preclinical research in immunocompetent murine models.

218 e human TCL patient-derived xenografts or an immunocompetent murine TCL model with a short course of

219 Using immunocompetent murine tumor models, we found that antib

220 ative and prophylactic treatments in healthy immunocompetent, MyD88-deficient, lymphocyte-deficient,

221 ytokine response in transplant recipients to immunocompetent, nontransplant recipients.

222 thobunyavirus, has only been identified in 3 immunocompetent North American patients with acute neuro

223 into immunodeficient NSG mice to generate an immunocompetent NSG/BM-GFP(+) (NSG-R) mouse model.

224 ents whereas arteritis was restricted to the immunocompetent ones.

225 not UV-B irradiation, was a prerequisite, as immunocompetent or UV-B-irradiated mice did not develop

226 ing infection with T. gondii in BALB/c mice, immunocompetent, or in severe combined immunodeficient m

227 ntigen receptor construct (chNKG2D) in fully immunocompetent orthotopic glioblastoma mouse models.

228 In an immunocompetent orthotopic glioma mouse model overexpres

229 c insights into this association in multiple immunocompetent orthotopic models of lung cancer.

230 In immunocompetent orthotopic mouse models of pancreatic ca

231 inib treatment also improves survival in the immunocompetent ovarian cancer mouse model system with I

232 eously in living tumors and across a diverse immunocompetent patient population may provide a foundat

233 Immunocompetent patients (18 to 60 years of age) with un

234 nth mortality was significantly higher among immunocompetent patients (39.0% vs. 22.0%, p = 0.047).

235 owever, data specific to GI-CMV infection in immunocompetent patients are comparatively limited.

236 Immunocompetent patients diagnosed with RT-PCR-confirmed

237 Significantly more immunocompetent patients were in the ICU at the time of

238 Immunocompetent patients were significantly older than i

239 ation would affect the development of KCs in immunocompetent patients with a history of multiple KCs.

240 be used selectively rather than routinely in immunocompetent patients with mild acute uncomplicated d

241 e presentation, evaluation, and treatment of immunocompetent patients with PCNSL.

242 In haemodynamically stable, immunocompetent patients younger than 85 years, primary

243 infection is usually limited to the skin in immunocompetent patients, usually as lymphocutaneous spo

244 tibody response to SARS-CoV-2, compared with immunocompetent patients.

245 follow an uneventful cataract extraction in immunocompetent patients.

246 and prevalences did not differ from those in immunocompetent patients.

247 ence and importance in immunocompromised and immunocompetent patients.

248 primary HCMV infection have been reported in immunocompetent patients.

249 tumor immunity was compromised compared with immunocompetent patients.

250 development, may be driven in part by HPV in immunocompetent patients.

251 vascular events between immunosuppressed and immunocompetent patients.

252 infection has a wide spectrum of severity in immunocompetent persons.

253 I], 8.7-15) in immunocompromised compared to immunocompetent persons; the case fatality rate was elev

254 ster (HZ), particularly in the unvaccinated, immunocompetent population, are needed to assess disease

255 oster (HZ), particularly in the unvaccinated immunocompetent population, are needed to assess disease

256 unocompromised populations and compare it to immunocompetent populations.

257 unocompromised populations and compare it to immunocompetent populations.

258 immunocompromised populations compared with immunocompetent populations.

259 toxicities is limited by a lack of suitable immunocompetent preclinical models.

260 Our studies in an immunocompetent preclinical mouse model demonstrate TAMs

261 cy on innate immune responses, we inoculated immunocompetent pregnant and nonpregnant female C57BL/6

262 SO treatment ameliorates colitis severity in immunocompetent rabbits, modulates LPMC immune responses

263 Here, an immunocompetent rat model was designed to recapitulate t

264 Herein, immunocompetent rats infected at birth with Pneumocystis

265 stemic donor-specific tolerance in otherwise immunocompetent rats, as evidenced by acceptance of seco

266 from donor mice shaped the virus kinetics in immunocompetent recipient hosts.

267 er of purified Tet2-Tet3 DKO iNKT cells into immunocompetent recipient mice resulted in an uncontroll

268 of neurological diseases, their survival in immunocompetent recipients is limited.

269 to produce long-term therapeutic benefit in immunocompetent recipients.

270 Using an immunocompetent SCLC mouse model, we demonstrated the sa

271 ain function of the thymus is to generate an immunocompetent set of T cells not reactive to self.

272 ttle is known about their biodistribution in immunocompetent settings.

273 -dose streptozocin (LD-STZ) treatment in the immunocompetent SKH1 mouse model of early stage diabetes

274 We show that MmuPV1 challenge of the outbred immunocompetent SKH1 strain produces both transient and

275 The lack of immunocompetent small animal models for hepatitis C viru

276 y post-entry, and has hindered developing an immunocompetent, small animal model.

277 A lack of immunocompetent-small-primate models has been an obstacl

278 Nine immunocompetent Sprague-Dawley rats received intravenous

279 Those with the immunocompetent SRS2 endotype had significantly higher m

280 We used an immunocompetent syngeneic HCC mouse model for the study.

281 o radiation therapy in vitro and in vivo (in immunocompetent syngeneic hosts).

282 of cancer-FOXP3 promoted the tumor growth in immunocompetent syngeneic mice but not in immunocompromi

283 PD-1) antibody alone or in combination in an immunocompetent syngeneic mouse model of ovarian cancer.

284 o significantly inhibited tumor growth in an immunocompetent syngeneic mouse model that better recapi

285 ing in vivo and ex vivo experiments with the immunocompetent TC-1 murine tumor model, we found that m

286 mmatory features were comparable between the immunocompetent Tg(+) and Rag1 (KO)/Tg(+) juveniles, the

287 As previously reported, immunocompetent Tg(+) juveniles exhibited spontaneous ne

288 iral load was negative in significantly more immunocompetent than immunocompromised (40.7% vs. 12.9%,

289 Significantly more immunocompetent than immunocompromised did not receive a

290 gnificantly higher mortality was observed in immunocompetent than in immunocompromised patients, but

291 Although most people are immunocompetent to the virus, a small group fail to moun

292 Hypothetical cohort of immunocompetent U.S. adults aged 50 years or older.

293 These recent HZ epidemiology data among an immunocompetent, unvaccinated population measure real-wo

294 ADCs had greater antitumor activity in immunocompetent versus immunodeficient mice, demonstrati

295 cape signature by comparing glioma growth in immunocompetent versus immunodeficient mice.

296 GI bleeding was the leading presentation in immunocompetent, while diarrhea and abdominal pain were

297 Here, we use immunocompetent wild-type mice to show that hNSC-derived

298 stinal mucormycosis even in patients who are immunocompetent without traditional risk factors.

299 CASE REPORT: A 30-year-old immunocompetent woman with complaints of an epigastric s

300 rier more frequently and causes mortality in immunocompetent zebrafish.